PRP and Integrative Chiropractic: Safety and Procedures

PRP and Integrative Chiropractic for El Paso Patients

Abstract

In this educational post, I guide you through the most common clinical questions patients and clinicians ask about platelet-rich plasma (PRP) therapy: FDA status and regulatory language, informed consent wording, practical steps to optimize platelet yield, and how to safely coordinate medications, exercise, and nutrition around a PRP procedure. Based on leading research teams and my clinical observations as Dr. Alexander Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, I explain how PRP devices are cleared, how procedures are regulated, why PRP is not classified as a drug, and how to frame consent in clear, ethical terms. I carefully review how platelets activate, stick together, and release growth factors; talk about how NSAIDs affect platelet function; summarize how high-intensity exercise and blood flow strategies can temporarily raise platelet counts; and share a chiropractic care plan that combines musculoskeletal biomechanics, vascular and autonomic tone, and tissue remodeling with PRP’s biological purpose. The aim is to present pragmatic, evidence-based guidance that is easy to understand and clinically actionable.

Introduction: A Clear Path Through PRP Questions Patients Ask

As a clinician who bridges chiropractic, advanced practice nursing, and functional medicine, I’ve found that PRP generates three core questions:

• Is PRP FDA-approved?
• What should my consent say?
• How can I improve my PRP quality and outcomes?

In this post, I answer and connect them to what really matters physiologically: platelets must be harvested, preserved, and activated in the right context to deliver a beneficial set of growth factors, cytokines, and extracellular vesicles to the target tissue. I also show you how integrative chiropractic care fits in—aligning biomechanics, neurovascular regulation, and inflammation control to amplify PRP’s regenerative potential.

FDA Status Explained: Devices, Procedures, and What “Approval” Really Means

Patients often ask: “Is PRP FDA approved?” Here’s how I explain it in practice.

• PRP is not a drug. It is an autologous biologic (derived from your blood) prepared and re-injected to concentrate platelets and their bioactive contents. Because PRP is you, not a manufactured pharmaceutical, it does not go through the FDA’s drug approval pathway.
• Devices versus procedures. The FDA can “clear” or “approve” medical devices used to prepare PRP under pathways such as 510(k) clearance, which indicates substantial equivalence to a predicate device (Food and Drug Administration, 2023a). Many centrifuges and PRP preparation kits are FDA cleared. However, drawing blood, concentrating platelets, and injecting them into a joint or tendon is a medical procedure, not a drug. The FDA does not “approve” medical procedures in the way it approves drugs for specific indications.
• Regulatory language matters. In counseling patients, I say: “The PRP kit I use is FDA-cleared as a device. PRP injections themselves are considered medical procedures that are widely used and supported by clinical studies, but they are not an FDA-approved drug treatment.” This distinction is truthful, ethical, and avoids implying that the procedure is “approved” like a medication for an indication.

Why PRP Is Not a Drug: Autologous Biologic and Minimal Manipulation

• Autologous origin: PRP is prepared from the patient’s own blood and returned to the patient. That relationship places it within the FDA’s framework for human cell, tissue, and cellular and tissue-based products (HCT/Ps) when minimally manipulated and used homologously (Food and Drug Administration, 2020).
• Minimal manipulation: When we follow standard protocols (e.g., centrifugation without altering fundamental biological characteristics), PRP is typically considered minimally manipulated and is not regulated as a drug or biologic requiring premarket approval (Food and Drug Administration, 2020).
• Clinical implication: Even if we had unlimited funding and perfect studies, PRP itself would not become a “drug” with a drug label because it is not manufactured and is patient-specific. Evidence still matters, but the regulatory path is different.

Informed Consent: Clear, Ethical, and Evidence-Guided

When obtaining consent, patients deserve precise language:

• What to include:
  • The PRP device/kit is FDA cleared for blood processing; the procedure is a widely used clinical technique rather than an FDA-approved drug therapy.
  • Known benefits: PRP may decrease pain, improve function, and support tissue healing in specific musculoskeletal conditions.
  • Risks/uncertainties: Pain at the injection site, bleeding, bruising, infection, transient inflammation flare; variable response because PRP biology differs among patients.
  • Alternatives: Physical therapy, integrative chiropractic care, medications, hyaluronic acid, steroid injections, surgery, and watchful waiting.
  • What is experimental? In several indications, PRP remains investigational with ongoing studies to refine formulations, timing, and indications (Food and Drug Administration, 2020; Fitzpatrick et al., 2017).
• Tone and transparency: I avoid calling PRP an “experiment” unless we are enrolling in a formal clinical trial. Instead, I say: “PRP is a procedure based on your own platelets with growing evidence in certain conditions. It is not an FDA-approved drug. Results can vary, and we will decide together if the balance of potential benefit and risk fits your goals.”

Physiology Primer: What Makes PRP Work

Understanding PRP’s physiology clarifies why the details of preparation matter.

• Platelet activation and release: Platelets store bioactive molecules in alpha-granules (e.g., PDGF, TGF-β, VEGF, IGF-1) and dense granules (ADP, serotonin, calcium). Upon activation, they release these factors, initiating chemotaxis, angiogenesis, cell proliferation, and extracellular matrix remodeling (Nurden, 2018).
• Aggregation mechanics: Platelets bind via GPIIb/IIIa (αIIbβ3) to fibrinogen and von Willebrand factor, forming a hemostatic plug and creating a microenvironment conducive to repair. Proper aggregation and activation at the target site is essential to delivering growth factors where they’re needed.
• Leukocyte content: PRP can be leukocyte-rich (LR-PRP) or leukocyte-poor (LP-PRP). LR may heighten early inflammatory signaling; LP may reduce catabolic cytokines in intra-articular applications. The choice depends on tissue type and clinical aim (DeLong et al., 2012).
• Fibrin architecture: The scaffold formed after activation (often via calcium chloride or thrombin) can influence growth factor release kinetics—slow, sustained release may better support tendon or ligament healing (Anitua et al., 2014).

NSAIDs and PRP: Why Medication Timing Matters

Patients frequently ask about NSAIDs around PRP. Here’s why timing matters:

• Platelet function: NSAIDs (particularly aspirin and other cyclooxygenase inhibitors) reduce thromboxane A2 synthesis, blunting platelet aggregation. In vitro, NSAIDs can disaggregate platelets and impair dense granule release, potentially diminishing PRP’s biologic potency (Warner & Mitchell, 2002).
• Clinical practice: I generally advise avoiding NSAIDs 10–14 days before and after PRP to protect platelet function and initial inflammatory signaling. When pain control is necessary, acetaminophen or topical agents may be preferred in the short term, individualized to the patient’s risk.
• Nuance: The literature is mixed for non-aspirin NSAIDs regarding the magnitude of platelet impairment, but the precautionary window reduces the risk of suboptimal activation in vivo. We weigh comorbidities (e.g., cardiovascular disease) and coordinate with the patient’s cardiologist if interrupting antiplatelet therapy is not possible.

Exercise to Boost Platelet Yield: What the Evidence Suggests

Transient, safe increases in circulating platelet counts may be achievable with short bouts of high-intensity exercise.

• Mechanism: Acute vigorous exercise induces catecholamine surges (epinephrine, norepinephrine), splenic contraction, and mobilization of platelets from marginal pools, temporarily raising platelet count and reactivity (Kuzeff et al., 2019).
• Protocol considerations:
  • A 10–20 minute bout of high-intensity interval cycling or brisk cardio shortly before phlebotomy may increase yield.
  • On-site options: A stationary bike or brief jumping jacks can be used for select patients.
  • Safety first: Screen for cardiovascular risk; avoid excessive strain in vulnerable patients; ensure adequate hydration.
• Clinical observation: In my practice, I often have patients perform a short, controlled HIIT circuit on a stationary cycle before a blood draw, when appropriate. While individual responses vary, it’s a low-risk strategy that may improve the quality and volume of PRP.

Blood Flow Restriction (BFR) and PRP: What We Know and Don’t Know

• Hypothesis: BFR training can alter vascular shear stress, metabolic byproduct signaling, and myokine release, potentially affecting platelet dynamics or growth factor milieu.
• Evidence status: Emerging studies have examined the effects of pre-procedure exercise on PRP yield, with mixed findings. BFR’s specific impact on PRP concentration or growth factor release remains uncertain and technique-dependent. Any application should be conservative and patient-specific.
• Practical approach: When using BFR in rehabilitation, I coordinate timing away from the immediate pre-phlebotomy period unless the patient is already accustomed and cleared. A simpler, safer approach for most is a brief, well-tolerated cardio bout.

The Core Principles

A helpful way I teach patients and teams is prioritization:

• High-impact factors:
  • The right indication: Tendinopathy, mild-to-moderate knee osteoarthritis, lateral epicondylitis—conditions with evidence supporting PRP’s benefit (Fitzpatrick et al., 2017; Laudy et al., 2015).
  • The right formulation and dose: Platelet concentration target, leukocyte profile (LR vs. LP), and activation strategy tailored to tissue.
  • Precision delivery: Ultrasound guidance to ensure accurate placement into the tendon or joint space.
  • Post-procedure loading: Structured rehab to leverage growth factor windows for collagen alignment and strength.
• Fine-tuning:
  • NSAID timing windows, brief pre-draw exercise, hydration, and diet tweaks—useful, but they matter less than indication, technique, and rehabilitation quality.

Prioritizing the big variables consistently produces better outcomes than fixating on marginal gains.

Integrative Chiropractic Care: Aligning Biomechanics With Biology

PRP’s bioactivity is only as good as the mechanical environment it encounters. This is where integrative chiropractic care seamlessly complements PRP:

• Biomechanical optimization: Targeted spinal and extremity adjustments can reduce aberrant joint loading, shear forces, and compensatory muscle patterns that perpetuate microtrauma. PRP is most effective when the target tissue is not continuously overloaded.
• Neuromuscular re-education: Proprioceptive training and motor control work (e.g., DNS-inspired patterns, closed-chain stability drills) establish cleaner movement patterns so healing tissues receive graded, appropriate stress.
• Fascial and soft tissue care: Myofascial release, instrument-assisted techniques, and perineural interface work reduce nociceptive input and improve tissue glide, facilitating perfusion and lymphatic flow into the healing region.
• Autonomic and vascular tone: Breathing mechanics, vagal modulation, and postural correction influence sympathetic/parasympathetic balance, which affects microvascular perfusion and inflammatory set points—key for PRP retention and nutrient delivery.
• Nutritional and functional medicine support: Anti-inflammatory nutrition, omega-3 balance, glycemic control, and micronutrient sufficiency (vitamin D, magnesium) tune the systemic milieu for repair and collagen synthesis (Calder, 2017).

Clinical Observations From My Practice

Across patients seen through my clinic and educational platforms (see dralexjimenez.com and my professional updates on LinkedIn), a few consistent patterns emerge:

• Patients with clean biomechanics and adherence to staged loading protocols after PRP report more reliable pain relief and functional gains at 6–12 weeks.
• Avoiding NSAIDs in the peri-procedural window is often associated with more robust early inflammatory signaling (the “good inflammation” that initiates reconstruction) and a smoother transition to the proliferative phases.
• Short, supervised high-intensity exercise before phlebotomy can modestly increase platelet counts in some patients, but outcomes hinge more strongly on precise injection technique and adherence to a graded rehabilitation plan.
• Integrating spinal and extremity adjustments with tendon-specific eccentric loading during weeks 1–6 post-PRP enhances collagen alignment and reduces recurrence in chronic tendinopathy.

Diet and PRP: Anti-Inflammatory Foundations

Nutrition shapes the inflammatory microenvironment into which PRP releases its signals.

• Core strategies:
  • Emphasize omega-3 fatty acids (EPA/DHA) to modulate eicosanoid balance and support the action of resolution-phase mediators (Calder, 2017).
  • Increase polyphenol-rich foods (berries, olives, green tea) to reduce oxidative stress and NF-κB activation.
  • Steady glycemic control to prevent hyperglycemia-induced glycation end products that stiffen collagen and impair microvascular flow.
  • Adequate protein to support collagen synthesis; consider timing vitamin C as a cofactor for proline/lysine hydroxylation in collagen formation.
• Hydration: Proper plasma volume supports venous access and centrifugation efficiency. Being well-hydrated pre-procedure is a simple, practical step.

Putting It All Together: A Practical PRP Care Pathway

Here is how I typically structure a PRP episode of care.

Pre-Procedure (7–14 days before)

• Review medications; plan NSAID hold when safe; coordinate with cardiology for antiplatelet therapy decisions.
• Begin an anti-inflammatory diet with an emphasis on omega-3s, polyphenols, and glycemic stability.
• Calm high-load activities on the target tissue; address biomechanics through chiropractic adjustments and movement cues.
• Hydrate well; assess sleep and stress (autonomic balance supports vascular tone).

Day of Procedure

• Consider a brief, supervised 10–15-minute HIIT cycle for eligible patients to possibly elevate platelet count.
• Confirm device sterilization and FDA-cleared PRP kit usage; verify consent language clarity about device clearance and procedure status.
• Use ultrasound guidance for accurate placement; tailor PRP formulation (LR vs LP) to tissue needs; avoid local anesthetics that may negatively affect platelets in the injectate.

Immediate Post-Procedure (0–72 hours)

• Expect transient inflammatory soreness; avoid NSAIDs to protect platelet activity and early signaling.
• Gentle mobility, breathwork, and pain control via acetaminophen or topical therapies as appropriate.
• Reinforce hydration and an anti-inflammatory diet.

Early Rehab (Days 3–14)

• Integrative chiropractic follow-up to maintain alignment and reduce compensatory strain.
• Initiate isometrics transitioning to eccentric loading for tendons; low-impact joint conditioning for intra-articular targets.
• Continue nutrition and sleep hygiene; monitor for adverse events.

Proliferative Phase (Weeks 2–6)

• Progress load using structured criteria (pain ≤3/10, no lagging swelling, quality of movement intact).
• Motor control drills and closed-chain stability to support collagen alignment.
• Reassess biomechanics and adjust care plan.

Remodeling and Return to Sport/Activity (Weeks 6–12)

• Introduce plyometrics or sport-specific loading as tolerated; monitor function, pain, and performance metrics.
• Maintain periodic chiropractic reassessments of joint mechanics and soft-tissue quality.

Common Patient Questions: Straight Answers

• “Is PRP FDA approved?” The PRP device may be FDA cleared; the procedure is a widely used clinical technique, not an FDA-approved drug.
• “Is PRP experimental?” PRP is evidence-supported for several musculoskeletal conditions, but it is not an FDA-approved drug therapy. We use the best available evidence and clinical judgment.
• “Should I stop NSAIDs?” Typically, yes, 10–14 days before and after PRP if safe. We will personalize this based on your medical history.
• “Should I exercise before the blood draw?” If you are cleared and comfortable, a brief high-intensity session can be helpful. We will supervise and tailor it to you.
• “Will blood flow restriction help?” Evidence is mixed; we prioritize safer, simpler options unless BFR is already part of your routine and medically cleared.

The Reasoning Behind Each Step

• We avoid NSAIDs to preserve platelet aggregation and granule release, enabling a robust repair signal.
• We use brief HIIT to mobilize platelets via sympathetic and splenic mechanisms, potentially improving PRP yield.
• We tailor PRP formulation (LR vs. LP) to match the inflammatory needs of the target tissue.
• We integrate chiropractic care to optimize mechanics and autonomic tone, ensuring PRP’s biologic activity is not undermined by persistent overload or poor perfusion.
• We sequence rehab to coincide with the kinetics of growth factor release and collagen remodeling timelines.

Limitations and Ongoing Research

PRP’s heterogeneity (inter-individual variability in platelet content, growth factor profiles, and leukocyte mix) means results vary. Device differences, spin times, and activation methods influence final composition. High-quality randomized trials continue to refine indications, protocols, and outcome predictors (Laudy et al., 2015; Fitzpatrick et al., 2017). Clinically, we mitigate variability by standardizing our preparation, documenting formulation, and matching it to the patient’s condition.

Conclusion: Aligning Biology, Biomechanics, and Behavior

PRP is at its best when we respect its physiology and place it within a carefully designed clinical ecosystem—right indication, right formulation, precise delivery, and an integrative plan that harmonizes biomechanics, vascular tone, and resolution of inflammation. With honest consent language, thoughtful medication timing, strategic exercise, and chiropractic integration, we provide PRP the conditions it needs to help patients move better and heal more completely.

---

References

• Food and Drug Administration. (2020). Regulatory considerations for human cells, tissues, and cellular and tissue-based products: Minimal manipulation and homologous use.
• Food and Drug Administration. (2023a). 510(k) premarket notification.
• Anitua, E., Prado, R., Orive, G., & de la Fuente, M. (2014). Platelet-rich plasma: Preparation and formulation. In Platelet-Rich Plasma (PRP) in Regenerative Medicine (pp. 1–20). Springer.
• Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochemical Society Transactions, 45(5), 1105–1115.
• DeLong, J. M., Russell, R. P., & Mazzocca, A. D. (2012). Platelet-rich plasma: Mechanisms of action and clinical applications. Orthopedic Clinics of North America, 43(2), 185–195.
• Fitzpatrick, J., Bulsara, M. K., McCrory, P. R., Richardson, M., & Zheng, M. H. (2017). Analysis of platelet-rich plasma composition for tendon and ligament healing: A systematic review. Sports Medicine, 47(3), 541–555.
• Kuzeff, A., et al. (2019). Exercise-induced changes in platelet count and function: Implications for cardiovascular health. Journal of Thrombosis and Haemostasis, 17(6), 1007–1019.
• Laudy, A. B., Bakker, E. W., Rekers, M., & Moen, M. H. (2015). Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: A systematic review and meta-analysis. British Journal of Sports Medicine, 49(10), 657–672.
• Nurden, A. T. (2018). Platelets, inflammation and tissue regeneration. Thrombosis and Haemostasis, 116(6), 949–960.
• Warner, T. D., & Mitchell, J. A. (2002). Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB Journal, 16(7), 789–804.